Mary Reumuth
Direttore Finanziario/CFO presso KALA BIO, INC.
Patrimonio netto: 488 571 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Eric Trachtenberg | M | 51 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 8 anni |
Howard Rosen | M | 66 | 10 anni | |
Jon Aron Olof Heimer | M | 57 | 4 anni | |
Mark Iwicki | M | 57 | 9 anni | |
Andrew Koven | M | 66 | 7 anni | |
Solange Bullukian | F | 59 | 3 anni | |
Carl Raimond | M | 53 | 4 anni | |
Fredrik Netzel | M | 55 | 5 anni | |
Johan Lund | M | 67 | 4 anni | |
Marjan Farid | M | 50 | 2 anni | |
Rickard El Tarzi | M | - | 5 anni | |
Gregory Perry | M | 63 | 6 anni | |
Todd Bazemore | M | 53 | 7 anni | |
Tommi Markus Unkuri | M | 44 | 5 anni | |
Robert Schueren | M | 62 | 2 anni | |
Mark Blumenkranz | M | 73 | 3 anni | |
Charles Myers | M | 70 | 3 anni | |
Jon Hindar | M | 68 | 3 anni | |
Nicolas Roelofs | M | 66 | 6 anni | |
Darius Kharabi | M | 45 | 3 anni | |
Anna Maria Marsell | F | 46 | 2 anni | |
Hannah Deresiewicz | F | - | - | |
Gregory Moore | M | 59 | 1 anni | |
Oskar Hjelm | M | 39 | 4 anni | |
Ida Grundberg | M | 41 | 5 anni | |
Romulus Brazzell | M | 71 | 11 anni | |
Linda Ramirez-Eaves | F | 52 | 5 anni | |
Bruno Rossi | M | - | 1 anni | |
Johan Holmner | M | - | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
James Levine | M | 53 | - | |
Janet Skogan Roemer | F | 68 | 6 anni | |
Robert A. Heft | M | 69 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 7 anni |
Alexander Fitzpatrick | M | 57 | 4 anni | |
Paulina Hill | M | 42 | 1 anni | |
Charles McDermott | M | 52 | 4 anni | |
Tina Nova | M | 70 | 1 anni | |
Raj Shah | M | 46 | 6 anni | |
Robert Paull | M | 47 | - | |
Gregory Grunberg | M | 51 | 7 anni | |
Gerald M. Haines | M | 61 | 2 anni | |
Robert Langer | M | 74 | 9 anni | |
Gustavo Salem | M | 60 | 3 anni | |
Robert Tepper | M | 68 | 9 anni | |
John F. Dee | M | 66 | 5 anni | |
Steven Zhang | M | - | - | |
Chen-Ming Yu | M | 50 | 1 anni | |
Vincent Kosewski | M | - | - | |
Barbara Littlefield | F | 66 | 4 anni | |
James Patnoe | M | - | - | |
Susan L. Coultas | M | - | 6 anni | |
John Miller | M | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 1 anni |
Kathleen McCann Kline | F | - | - | |
Michele LaRussa | F | 54 | - | |
Niranjan Kameswaran | M | - | - | |
John R. Malloy | M | 65 | 2 anni | |
Stephen P. Toon | M | - | 2 anni | |
Gregory Powers | M | - | 2 anni | |
Julie Smith | F | 53 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 4 anni |
Geoffrey Peter Hazlewood | M | 73 | 7 anni | |
Thomas Schuetz | M | 63 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 5 anni |
Kevin Bitterman | M | 47 | - | |
Kevin R. Bracken | M | 75 | - | |
Fredric D. Price | M | 78 |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | 6 anni |
John A. McCarthy | M | 65 | 1 anni | |
Melvin I. Simon | M | 85 | 14 anni | |
Mark Leschly | M | 55 | 10 anni | |
William Baum | M | 79 | 13 anni | |
Simon B. Rich | M | 80 | 3 anni | |
Josiah Craver | M | - | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 45 | 65.22% |
Svezia | 19 | 27.54% |
Canada | 6 | 8.70% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Mary Reumuth
- Contatti personali